At Sygnature Discovery we are committed to adding value to our client’s programs by providing relevant and innovative solutions to their discovery programs. Our experienced scientists regularly engage with the drug discovery community to share our recent advances, expert opinion and updates on our successful collaborations, helping Sygnature to remain at the leading edge of scientific advances. Download our most recent scientific presentations here.
Building a modern screening library and infrastructure
Many organisations have inherited a legacy library and screening infrastructure which in some cases has been tweaked to reflect modern thinking on lead-like properties and toxicity liabilities or improved informatics. At Sygnature we have...
FIND OUT MOREEnabling success in lead identification
Optimising Compound Libraries for Novel Lead Identification: Balancing Diversity and Hit Validation. Join our talk to learn strategies.
FIND OUT MOREBetter trials demand better oncology drugs…
Discover better oncology drugs and redefine cancer trials. Explore unmet needs and new perspectives in drug discovery. Join the shift towards personalised treatments for patients.
FIND OUT MOREA Breath of Fresh Air: Delivering Novel Respiratory Syncytial Virus (RSV) Inhibitors
Unveiling PC786: A potent RSV inhibitor. Safer & effective inhaled treatment for respiratory infections. Pulmocide & Sygnature collaboration.
FIND OUT MORESmarter IDO inhibitor profiling using biophysical, biochemical and cellular target engagement approaches
Smarter IDO Inhibitor Profiling: Biophysical, Biochemical & Cellular Approaches. Discover an efficient strategy for characterising hit compounds, enhancing hit-to-lead drug discovery projects.
FIND OUT MORE